Search Results

There are 14509 results for: content related to: S-allylcysteine, a water-soluble garlic derivative, suppresses the growth of a human androgen-independent prostate cancer xenograft, CWR22R, under in vivo conditions

  1. Microarray analysis of prostate cancer progression to reduced androgen dependence: Studies in unique models contrasts early and late molecular events

    Molecular Carcinogenesis

    Volume 41, Issue 3, November 2004, Pages: 150–163, F.M. Sirotnak, Yuhong She, Nushmia Z. Khokhar, Paula Hayes, William Gerald and Howard I. Scher

    Version of Record online : 23 SEP 2004, DOI: 10.1002/mc.20051

  2. You have free access to this content
    Androgenic regulation of growth factor and growth factor receptor expression in the cwr22 model of prostatic adenocarcinoma

    International Journal of Cancer

    Volume 82, Issue 3, 30 July 1999, Pages: 424–429, Russell B. Myers, Denise Oelschlager, Upender Manne, Patricia N. Coan, Heidi Weiss and William E. Grizzle

    Version of Record online : 10 NOV 1999, DOI: 10.1002/(SICI)1097-0215(19990730)82:3<424::AID-IJC16>3.0.CO;2-B

  3. You have free access to this content
    Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r

    Magnetic Resonance in Medicine

    Volume 62, Issue 5, November 2009, Pages: 1112–1119, H. Carl Le, Mihaela Lupu, Khushali Kotedia, Neal Rosen, David Solit and Jason A. Koutcher

    Version of Record online : 24 SEP 2009, DOI: 10.1002/mrm.22137

  4. Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line

    The Prostate

    Volume 76, Issue 12, September 1, 2016, Pages: 1067–1077, Mojgan Shourideh, Adam DePriest, James L. Mohler, Elizabeth M. Wilson and Shahriar Koochekpour

    Version of Record online : 8 JUN 2016, DOI: 10.1002/pros.23190

  5. You have full text access to this OnlineOpen article
    Metastatic phenotype in CWR22 prostate cancer xenograft following castration

    The Prostate

    Volume 76, Issue 4, March 1, 2016, Pages: 359–368, Steven J. Seedhouse, Hayley C. Affronti, Ellen Karasik, Bryan M. Gillard, Gissou Azabdaftari, Dominic J. Smiraglia and Barbara A. Foster

    Version of Record online : 8 DEC 2015, DOI: 10.1002/pros.23127

  6. You have free access to this content
    FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer

    International Journal of Cancer

    Volume 117, Issue 6, 20 December 2005, Pages: 1039–1048, Chee-Wai Chua, Davy Tak-Wing Lee, Ming-Tat Ling, Chun Zhou, Kwan Man, Joanna Ho, Franky L. Chan, Xianghong Wang and Yong-Chuan Wong

    Version of Record online : 28 JUN 2005, DOI: 10.1002/ijc.21243

  7. Docetaxel increases antitumor efficacy of oncolytic prostate-restricted replicative adenovirus by enhancing cell killing and virus distribution

    The Journal of Gene Medicine

    Volume 12, Issue 6, June 2010, Pages: 516–527, Xiong Li, Youhong Liu, Yong Tang, Phipps Roger, Meei-Huey Jeng and Chinghai Kao

    Version of Record online : 17 MAY 2010, DOI: 10.1002/jgm.1462

  8. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer

    The Prostate

    Volume 72, Issue 14, 1 October 2012, Pages: 1491–1505, John T. Isaacs, Jason M. D'Antonio, Shuangling Chen, Lizamma Antony, Susan P. Dalrymple, Georges H. Ndikuyeze, Jun Luo and Samuel R. Denmeade

    Version of Record online : 6 MAR 2012, DOI: 10.1002/pros.22504

  9. 5α-reductase type 3 enzyme in benign and malignant prostate

    The Prostate

    Volume 74, Issue 3, February 2014, Pages: 235–249, Mark A. Titus, Yun Li, Olga G. Kozyreva, Varun Maher, Alejandro Godoy, Gary J. Smith and James L. Mohler

    Version of Record online : 22 OCT 2013, DOI: 10.1002/pros.22745

  10. You have free access to this content
    Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro

    International Journal of Cancer

    Volume 115, Issue 4, 1 July 2005, Pages: 630–640, Claudio Festuccia, Giovanni Luca Gravina, Adriano Angelucci, Danilo Millimaggi, Paola Muzi, Carlo Vicentini and Mauro Bologna

    Version of Record online : 7 FEB 2005, DOI: 10.1002/ijc.20917

  11. Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer

    Journal of Cellular Physiology

    Cuicui Zhu, Qingyi Zhu, Zhaomeng Wu, Yingying Yin, Dan Kang, Shan Lu and Ping Liu

    Version of Record online : 24 MAY 2017, DOI: 10.1002/jcp.25968

  12. Galeterone and VNPT55 disrupt Mnk-eIF4E to inhibit prostate cancer cell migration and invasion

    The FEBS Journal

    Volume 283, Issue 21, November 2016, Pages: 3898–3918, Andrew K. Kwegyir-Afful, Robert D. Bruno, Puranik Purushottamachar, Francis N. Murigi and Vincent C.O. Njar

    Version of Record online : 1 OCT 2016, DOI: 10.1111/febs.13895

  13. Up-Regulation of Follistatin-Like 1 By the Androgen Receptor and Melanoma Antigen-A11 in Prostate Cancer

    The Prostate

    Volume 77, Issue 5, April 1, 2017, Pages: 505–516, Shifeng Su, Amanda B. Parris, Gail Grossman, James L. Mohler, Zengjun Wang and Elizabeth M. Wilson

    Version of Record online : 14 DEC 2016, DOI: 10.1002/pros.23288

  14. You have free access to this content
    Control of prostate cell growth: BMP antagonizes androgen mitogenic activity with incorporation of MAPK signals in Smad1

    The EMBO Journal

    Volume 26, Issue 2, January 24, 2007, Pages: 346–357, Tao Qiu, William E Grizzle, Denise K Oelschlager, Xing Shen and Xu Cao

    Version of Record online : 21 DEC 2006, DOI: 10.1038/sj.emboj.7601499

  15. Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity

    The Prostate

    Volume 70, Issue 12, 1 September 2010, Pages: 1286–1294, Kenji Kuroda, He Liu, Sae Kim, Ming Guo, Vincent Navarro and Neil H. Bander

    Version of Record online : 5 APR 2010, DOI: 10.1002/pros.21164

  16. You have full text access to this OnlineOpen article
    Src controls castration recurrence of CWR22 prostate cancer xenografts

    Cancer Medicine

    Volume 2, Issue 6, December 2013, Pages: 784–792, Bing Su, Bryan Gillard, Lingqiu Gao, Kevin H. Eng and Irwin H. Gelman

    Version of Record online : 11 OCT 2013, DOI: 10.1002/cam4.144

  17. You have full text access to this Open Access content
    Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11[RIGHTWARDS ARROW]miRNA-541[RIGHTWARDS ARROW]androgen receptor (AR)[RIGHTWARDS ARROW]MMP9 signaling

    Molecular Oncology

    Volume 9, Issue 1, January 2015, Pages: 44–57, Shuai Hu, Lei Li, Shuyuan Yeh, Yun Cui, Xin Li, Hong-Chiang Chang, Jie Jin, Chawnshang Chang

    Version of Record online : 29 JUL 2014, DOI: 10.1016/j.molonc.2014.07.013

  18. Positive impact of a master of science in applied anatomy program on USMLE Step 1 performance

    Anatomical Sciences Education

    Volume 8, Issue 1, January/February 2015, Pages: 31–36, John R. Fredieu and Clint W. Snyder

    Version of Record online : 14 APR 2014, DOI: 10.1002/ase.1455

  19. Co-Delivery of Docetaxel and p44/42 MAPK siRNA Using PSMA Antibody-Conjugated BSA-PEI Layer-by-Layer Nanoparticles for Prostate Cancer Target Therapy

    Macromolecular Bioscience

    Volume 17, Issue 5, May 2017, See-Tong Pang, Feng-Wei Lin, Cheng-Keng Chuang and Hung-Wei Yang

    Version of Record online : 27 JAN 2017, DOI: 10.1002/mabi.201600421

  20. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor

    The Prostate

    Volume 75, Issue 11, August 1, 2015, Pages: 1187–1196, Yan Wang, Gaolei Liu, Dali Tong, Henna Parmar, Donald Hasenmayer, Wenqiang Yuan, Dianzheng Zhang and Jun Jiang

    Version of Record online : 20 APR 2015, DOI: 10.1002/pros.23000